Business Wire

ORAL-B

7.3.2023 08:01:41 CET | Business Wire | Press release

Share
Oral-B® Announces Launch of THE BIG RETHINK, an Initiative to Make Oral Care More Inclusive, Accessible, and Positive for People With Disabilities, Their Caregivers, and Dental Professionals.

Oral-B, a leading innovator in oral health is on a mission to change this with the launch of THE BIG RETHINK, its social ambition to ensure that everybody has an equitable oral care experience - whether that’s at home or in the dentist’s chair. The brand, who is at the beginning of this journey recognizes the need to continue learning from both dental professionals and consumers who frequently experience oral health struggles to be able to make a real impact and offer an equitable oral care experience for everyone.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230228006117/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Oral-B launches The Big Rethink initiative at exclusive launch event in Frankfurt with panel of experts on how to make oral care more inclusive and accessible. Pictured (left to right): British broadcaster, Nikki Fox, Executive Board Member of the iADH, Alison Dougall, British influencer James Hunt from Stories About Autism, iADH spokesperson, Johanna Norderyd, popular German actor, Andre Dietz, Chief Executive Officer for Healthcare, Jennifer Davis and P&G Europe Oral Care Senior Vice President, Benjamin Binot. (Photo: Business Wire)

To launch THE BIG RETHINK campaign, the brand is working together with the International Association for Disability and Oral Health (iADH) to help inform the approach. The first step of this partnership is the launch of the ‘Positive Practices’ programme, designed to train and educate dental practices on how to become more confident and inclusive when it comes to their patients. The programme will not only enable Oral-B to become more educated on the physical and mental needs of those with different types of disabilities, but it will also help them to learn how to adapt their product offering and improve the oral health outcomes of those with disabilities. THE BIG RETHINK Content Hub will also offer relevant and helpful content for people with disabilities, their caregivers and families, as well as the professional dental health community. Visit: https://www.oralb.co.uk/en-gb/big-rethink.

As Oral-B celebrates 60 years since the launch of the first electric toothbrush in 1963, the brand continues to put consumer understanding and leading-edge technology at the heart of its product development by designing inclusive products that help to bring about positive change in oral care for everyone. The brand is also developing a series of tools to support dentists within their practices, such as student training and accreditation programmes.

To celebrate the launch of THE BIG RETHINK, a brand film was unveiled last night at an exclusive launch event in Frankfurt, Germany. The event was an opportunity for Oral-B to set out its ambitions of THE BIG RETHINK and discuss the findings of The Oral Health & Disability European Study with an influential panel of speakers. Including P&G’s Chief Executive Officer for Healthcare, Jennifer Davis, iADH spokesperson, Johanna Norderyd, British broadcaster, Nikki Fox, British influencer James Hunt from Stories About Autism and popular German actor, Andre Dietz.

Jennifer Davis, P&G Chief Executive Officer, Healthcare says: “As a leading innovator in oral health for over 70 years and the world’s #1 dentist recommended toothbrush brand, we recognise the importance of making oral care accessible to all. We are indeed at the beginning of a very exciting journey, and we will continue to learn from both dental professionals and consumers to ensure we are creating positive oral care solutions for everyone – I really believe that this is the beginning of an initiative that has a global footprint.”

Benjamin Binot, P&G Europe Oral Care Senior Vice President comments: “Addressing the significant oral health inequalities experienced by people with disabilities in Europe is a huge priority for Oral-B. Our research shows that today, there are many oral health struggles amongst this audience – 1 in 5 (20%) of those with severe disabilities find brushing all their teeth physically challenging* and over a third of people with disabilities feel anxious or frustrated when it comes to visiting the dentist*. We want to help change this and believe that everyone should have an equitable oral health experience. Through our work with the iADH and the creation of the Positive Practices programme, we want to not only provide dental practices with educational materials to make their practices more inclusive, but also give the disabled community the tools they need to have more autonomy over their own oral health.

Alison Dougall, Professor in Special Care Dentistry, and an Executive Board member of iADH says; “We are delighted to have partnered with Oral-B to address the oral health struggles that are experienced by people with disabilities in Europe. Our shared values will enable us to make a huge difference to the oral care experience for people living with visible and nonvisible disabilities. We recognise that many healthcare professionals have not received education in special care dentistry during their training, and so by raising awareness around the issue and supporting those with disabilities, we can help to make small but significant adjustments to their oral health routines.”

-ENDS-

About Oral-B
Oral-B® exists to help people Brush Like a Pro. Oral-B® was founded in 1950 by a California periodontist, who invented an innovative toothbrush to help his patients achieve healthier teeth and gums at home. Oral-B® continues to stay true to his mission and is today the worldwide leader in the over $5 billion brushing market. Part of the Procter & Gamble Company, the brand manufactures electric toothbrushes and toothpaste for adults and children, oral irrigators, and interdental products.

About the research
– The Oral Health & Disability European Study – UK, France, Germany and Italy, was conducted by Reputation Leaders.

– The studies were conducted between 2021 – 2022 in Germany (n=1034), France (n=1009), UK (n=2029) and Italy (n=1002). In each country the online survey sample was recruited and reported to be representative of the total adult population by age, gender and region.

– The margin of error of a sample of 5000 adults is +/- 1.4% at a 95% confidence level for the 4 leading economies.

– At a country level, the margin of error of the sample relative to the total adult population was UK n=2000 (+/- 2.2%), Germany, France and Italy, n=1000 (+/- 3.1%)

+ Assumes total EU and UK population, 2022

About The iADH (International Association for Disability and Oral Health)
The iADH is a global organization with over 8000 members from all sectors of health and social care interested in disability and oral health who work to share their scientific knowledge, research, clinical skills and collective experience to reduce barriers to care and improve oral health outcomes for people with disability.

For more information, please visit: https://www.oralb.co.uk

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230228006117/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Merz Therapeutics and Kvvit Enter Exclusive Agreement for INBRIJA® (levodopa inhalation powder) in Mainland China, Hong Kong and Macao26.5.2026 09:00:00 CEST | Press release

Kvvit to lead local development, regulatory activities and commercialization of INBRIJA® in mainland China, Hong Kong and Macao​ Under the agreement, Merz Therapeutics will receive upfront, development and commercial milestone payments, and tiered supply and royalty arrangements, with no manufacturing rights granted to Kvvit​ Merz Therapeutics GmbH and Jiangxi Kvvit Pharmaceutical Co. Ltd. today announced that the companies have entered into an exclusive license and collaboration agreement regarding INBRIJA® (levodopa inhalation powder) and its proprietary inhalation device for the intermittent treatment of episodic motor fluctuations (OFF episodes) in adult patients with Parkinson’s disease (PD) treated with a levodopa/dopa-decarboxylase inhibitor in mainland China, Hong Kong and Macao.​ Under the agreement, Merz will supply INBRIJA® and retain responsibility for global product quality and key regulatory activities. Kvvit will lead development, regulatory activities and commercializat

Poland’s Poznan University of Technology Unveils IQM Quantum Computer to Drive Research and Education26.5.2026 08:49:00 CEST | Press release

IQM Radiance R1 is the first on-premises quantum computer for the PUT. The university aims to use the system to spearhead quantum education and research while boosting STEM in the country. This is the second operational quantum computer deployed in Poland by IQM. The university recognizes the significant long-term potential of integrating quantum computing, artificial intelligence, and high-performance computing (HPC), and intends to play a key role in shaping this transformation in Europe. Poznan University of Technology (PUT) has launched its first locally installed quantum computer, deployed by IQM Quantum Computers, to advance education and scientific research in the field of quantum technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260525424085/en/ The moment Poland switched on IQM's second quantum computer. Minister of Science and Higher Education Dr. Marcin Kulasek, IQM CEO Jan Goetz and CCO Sylwia de Weyde

BearingPoint Introduces Fully Sovereign On-Premise Infrastructure for GenAI and Agentic AI in Europe26.5.2026 08:30:00 CEST | Press release

BearingPoint is expanding its AI portfolio with a fully owned, sovereign on-premise and edge infrastructure designed specifically for generative and agentic AI workloads in highly regulated industries and public administrations in Europe. Building on decades of experience operating its own sovereign cloud, the firm now offers clients both dedicated hardware and token-based access to large language models – fully GDPR-compliant, ISO-certified and, on request, NIS2- and DORA-ready BearingPoint announces the launch of the BearingPoint Fully-Owned Sovereign Infrastructure Stack, an infrastructure platform designed, operated, and managed entirely by BearingPoint for GenAI and agentic AI applications, consistently engineered for European sovereignty, compliance, and security. With its own data center in Graz, the solution enables companies and public institutions to run sensitive AI workloads in fully controlled, EU-based environments – from initial innovation projects to mission-critical sc

Bial Announces Completion of Phase 2b ACTIVATE Study with BIA 28-6156 in GBA1-Associated Parkinson’s26.5.2026 08:00:00 CEST | Press release

Study Topline results will be released around the end of Q2 2026 BIA 28-6156 is being developed as a potential first-in-class disease-modifying therapy in GBA-PD Bial was present at the GBA1 conference and is currently attending the World Parkinson Congress Bial, an innovation-driven biopharmaceutical company focused on neurosciences and rare diseases, today announced the completion of the treatment period in its Phase 2b ACTIVATE study of BIA 28-6156 (pariceract) in patients with Parkinson’s disease (PD) who have a pathogenic mutation in the glucocerebrosidase 1 (GBA1) gene (GBA-PD). Upon completion of the 78-week double-blind treatment period and all scheduled safety follow-ups, data cleaning and analysis are currently ongoing. Topline results will be released around the end of Q2. A status report on the ACTIVATE study was presented in an oral presentation at the 3rd International GBA1 Meeting 2026. The team is currently attending the 7th World Parkinson Congress, taking place in Pho

Oticon Medical Introduces Ponto™ Instant, Expanding Non-Surgical Choice with Instant HearBand and Instant SoundConnector26.5.2026 07:00:00 CEST | Press release

Oticon Medical today announces its new non-surgical portfolio, Ponto Instant, designed to broaden access to bone conduction hearing and offer more choice for users and hearing care professionals. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260525771593/en/ Left: Instant HearBand, a discreet behind-the-head wearable solution that offers an alternative to Softband 5. Right: Instant SoundConnector, a small accessory fitted to a cap or other headwear, providing another non-surgical way to wear a Ponto sound processor. The Ponto Instant portfolio includes Softband 5, Oticon Medical’s established and trusted non-surgical solution, and now expands with the launch of Instant HearBand and Instant SoundConnector, further strengthening its wearable offering for children and adults who prefer a non-surgical solution. Instant HearBand: a discreet new wearable alternative As part of the new portfolio, Instant HearBand is introduced as

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye